Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 31, 2018
Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7
SAN DIEGO, Oct. 31, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that the Company will release its third quarter 2018 financial results and provide ...
October 31, 2018
CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018
MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
October 30, 2018
Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018
WATERTOWN, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical stage leader in the field of stabilized, cell-permeable peptides to treat cancer ...
October 30, 2018
Prothena to Report Third Quarter 2018 Financial Results on November 6
DUBLIN, Ireland, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and ...
October 30, 2018
CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6
NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
October 30, 2018
Inventiva invited to present at Stifel 2018 Healthcare Conference in New York and at Jefferies 2018 London Healthcare Conference
Daix (France), October 30, 2018 - Inventiva S.A. ("Inventiva" or the "Company"), a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) ...
October 30, 2018
OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress
NANTES, France, Oct. 30, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnémo: OSE) presented at the World Immunotherapy Congress held on Oct. 29-31, 2018 ...
October 30, 2018
NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
NEC Corporation (NEC; TSE: 6701) and Transgene (TNG.PA) (Euronext Paris: TNG) today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration ...
October 30, 2018
InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing
JENA, Germany, Oct. 30, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting the ...
October 30, 2018
Navicent Health Adopts iCAD’s Breast Cancer Detection and Therapy Solutions to Enhance Patient Care
NASHUA, N.H., and MACON, Ga., Oct. 30, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, ...
October 30, 2018
Mustang Bio Announces Updates on CAR T Cell Therapy Clinical Trials with City of Hope
NEW YORK, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary ...
October 30, 2018
CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates
NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), today announced that the company has initiated the seladelpar Phase 3 registration study ...
October 30, 2018
BioTime to Report Third Quarter 2018 Financial Results on November 8th, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its third ...
October 30, 2018
STRATA Skin Sciences to Host 3rd Quarter 2018 Financial Results and Business Update Conference call on Tuesday, November 13, 2018
HORSHAM, Pa., Oct. 30, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
October 30, 2018
FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma’s UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)
UroGen Pharma Ltd. (URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today ...
October 30, 2018
InspireMD to Report Third Quarter 2018 Financial Results and Provide Business Update on Tuesday, November 6
TEL AVIV, Israel, Oct. 30, 2018 (GLOBE NEWSWIRE) --  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention ...
October 29, 2018
OncoCyte Completes Successful Transition to New Diagnostic Testing Platform and Initiates DetermaVu™ Development Studies
ALAMEDA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, ...
October 29, 2018
OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
NANTES, France, Oct. 29, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnémo: OSE) today announced publication in Nature Communications of its monoclonal antibody (OSE-127) targeting ...
October 29, 2018
Genkyotex Announces Positive Outcome from the Independent SMB’s Third Pre-Planned Review of the Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies (the “Company”), announces today that the ...
October 29, 2018
AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620
Lausanne, Switzerland, October 29, 2018 - AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced that its partner Life ...
Page 8 of 117